Document Detail

Fatty liver: role of inflammation and fatty acid nutrition.
MedLine Citation:
PMID:  20189787     Owner:  NLM     Status:  MEDLINE    
Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver damage, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. NAFLD is strongly associated with insulin resistance and is defined by accumulation of liver fat >5% per liver weight in the presence of <10g of daily alcohol consumption. The exact prevalence of NAFLD is uncertain because of the absence of simple noninvasive diagnostic tests to facilitate an estimate of prevalence but in subgroups of people such as those with type 2 diabetes, the prevalence may be as high as 70%. NASH is an important subgroup within the spectrum of NAFLD that progresses over time with worsening fibrosis and cirrhosis, and NASH is associated with increased risk for cardiovascular disease. It is, therefore, important to understand the pathogenesis of NASH specifically, to develop strategies for interventions to treat this condition. The purpose of this review is to discuss the roles of inflammation, fatty acids and fatty acids in nutrition, in the pathogenesis and potential treatment of NAFLD.
Christopher D Byrne
Related Documents :
522917 - Effect of chloro- and bromo-derivatives of isocrotonic acid of bioenergetic processes i...
1729767 - Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six stru...
11692217 - Influence of n-acetylcysteine on hepatic amino acid metabolism in patients undergoing o...
3391177 - Uptake and intracellular transport in rat liver of formaldehyde-treated bovine serum al...
1690007 - Histamine release from rat mast cells induced by metabolic activation of polyunsaturate...
2504167 - Omega- and (omega-1)-hydroxylation of lauric acid and arachidonic acid by rat renal cyt...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-03-02
Journal Detail:
Title:  Prostaglandins, leukotrienes, and essential fatty acids     Volume:  82     ISSN:  1532-2823     ISO Abbreviation:  Prostaglandins Leukot. Essent. Fatty Acids     Publication Date:    2010 Apr-Jun
Date Detail:
Created Date:  2010-04-19     Completed Date:  2010-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8802730     Medline TA:  Prostaglandins Leukot Essent Fatty Acids     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  265-71     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Institute for Developmental Sciences, University of Southampton and Southampton University Hospitals Trust, Southampton, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fatty Acids / metabolism*
Fatty Acids, Omega-3 / therapeutic use
Fatty Liver / drug therapy,  metabolism*,  physiopathology
Inflammation / metabolism*,  physiopathology
Insulin Resistance
Liver / drug effects,  metabolism,  pathology
Models, Biological
Oxidative Stress*
Reg. No./Substance:
0/Fatty Acids; 0/Fatty Acids, Omega-3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil ag...
Next Document:  Polyunsaturated fatty acids in the modulation of T-cell signalling.